Anti-amyloid antibodies
Infused antibodies can lower amyloid in early Alzheimer’s disease. They need monitoring for brain swelling or bleeding on MRI.
Overview
Lecanemab and donanemab are approved examples in the US for early symptomatic disease after amyloid confirmation. Aducanumab’s Alzheimer’s indication was withdrawn.
How it works
Monoclonal antibodies bind aggregated amyloid and promote clearance, with ARIA as a key risk.
Latest papers
topQuery for this technology: (TITLE:"Anti-amyloid antibodies" OR ABSTRACT:"Anti-amyloid antibodies") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Anti-amyloid antibodies, not a curated reading list.
Similar pages
not linked directly; found by shared links- TechnologyApoE testing
Shares Donanemab, Lecanemab, Alzheimer’s disease and the tag dementia-atlas.
- TermARIA
Shares Donanemab, Lecanemab, Alzheimer’s disease and the tag dementia-atlas.
- CompanyBiogen
Shares Aducanumab, Lecanemab, Alzheimer’s disease and the tag dementia-atlas.
- RoadmapAnti-amyloid medicines
Shares Aducanumab, Donanemab, Lecanemab, Alzheimer’s disease and the tag dementia-atlas.
- IdeaAntibody trials that enrol mixed and comorbid disease
Shares Donanemab, Lecanemab, Alzheimer’s disease and the tag dementia-atlas.
- TargetAmyloid-beta
Shares Donanemab, Lecanemab, Alzheimer’s disease and the tag dementia-atlas.
- TrialTRAILBLAZER-ALZ 2
Shares Donanemab, Alzheimer’s disease and the tag dementia-atlas.
- TrialENGAGE
Shares Aducanumab, Alzheimer’s disease and the tag dementia-atlas.